Report from Biovica's Annual General Meeting on August 29, 2019

Below is a summary of the decisions made at the Annual General Meeting, AGM.

The Meeting resolved that available funds of SEK 32,698,918 will be carried forward.

The Meeting resolved that the renumeration for the Board of Director’s will be SEK 150,000 for Directors and SEK 400,000 for the Chairman of the Board. The Meeting also resolved that the auditors should be paid according to approved account.

Board members for the period until the end of the next Annual General Meeting were re-elected: Lars Holmqvist, Maria Holmlund, Ulf Jungnelius, Anders Rylander and Jesper Söderqvist. Henrik Osvald was elected as a new board member. Lars Holmqvist was elected Chairman of the Board.

Grant Thornton Sweden AB was elected as the company’s auditor, with Stéphanie Ljungberg as Auditor in Charge.

The AGM resolved in accordance with the proposals submitted:

  • Amendments to the Articles of Association regarding share capital, number of shares and notice.
  • Guidelines for renumeration to senior executives
  • Process for appointing and work instructions for election committee.
  • Resolution to authorize the Board to issue new shares of up to 20% of the current number of shares.
  • Employee stock option plan for 270,000 options.

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Read more: www.biovica.com

Tags:

About Us

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Subscribe

Media

Media

Documents & Links